ADA Leaders Resign Amid Researcher Ejections

The journal's third 2026 editorial targets a sweeping OMB proposal to overhaul federal grantmaking — even as five researchers, including the Editor-in-Chief, are removed from the ADA's annual meeting.

By
Conexiant News Staff
June 10, 2026
4 min

Conexiant

Overview

The American Diabetes Association's editorial board has published a critical response to proposed federal research policies, leading to the resignation of key leaders following the ejection of researchers at a recent conference.

Background

The proposed changes to federal research policy could significantly impact the landscape of biomedical research funding in the United States. The American Diabetes Association (ADA) has raised alarms about the shift from expert peer review to political appointee oversight.

Data Highlights

No numerical or trial data was provided in the source material.

Key Findings

The ADA's editorial board published an editorial opposing a proposed federal rule that would allow political appointees to influence grant decisions.
Five researchers, including ADA Editor-in-Chief Steven E. Kahn, were expelled from the ADA's 2026 Scientific Sessions for distributing a critical editorial.
Resignations of ADA leaders followed the expulsions, indicating internal conflict regarding the organization's stance on federal research funding.
The editorial authors criticized the proposed rule for potentially damaging peer review and institutional autonomy.
Historical data cited in the editorial indicated a significant decline in NIH funding opportunities since the return of the Trump administration.

Clinical Implications

The proposed changes to federal grantmaking could restrict funding for critical diabetes research, impacting the development of new therapies and interventions. Clinicians should remain informed about these policy changes as they may affect the availability of resources for diabetes care and research.

Conclusion

The ongoing debate over federal research policy and its implications for the ADA highlights the tension between scientific integrity and political influence in biomedical research funding.